In the shadow of every viral outbreak lies a deeper challenge: how do we deliver therapeutics precisely, safely, and effectively to the cells that need them most? While vaccine development and antiviral discovery often dominate headlines, the unsung hero of modern virology may well be lipid-based drug delivery systems. These microscopic carriers—liposomes, lipid nanoparticles (LNPs), and...
When immune checkpoint antibodies first entered the clinic a decade ago, they were hailed as a revolution. Drugs targeting PD‑1 and CTLA‑4 rewrote the rules of oncology, offering durable responses in cancers once considered untreatable. Today, the story is less about discovery and more about refinement: how to manufacture these complex molecules at scale, how to test them in ever more realistic...
That simple statement captures why glycoproteins have become one of the most compelling frontiers in biomedical research. These sugar‑coated proteins are not passive ornaments; they are active messengers, shaping how cells talk, how the immune system responds, and how diseases unfold.
When Sugar Codes Go Wrong
Glycosylation in health and disease represents one of the most...
Improve CRISPR screening confidence with custom gRNA library design and nuclease activity measurement for gene editing, diagnostics, and therapeutic R&D.
CRISPR-based screening has become a practical engine for functional genomics, target discovery, and gene therapy research. But the quality of a screen often depends on two upstream decisions: how well the guide RNA library is...
The complement system acts as a double-edged sword. While it is a guardian of innate immunity, its uncontrolled activation—marked by the rapid opsonization of surfaces with C3b fragments—is a primary driver of tissue damage in rare diseases and chronic inflammation.
For drug developers, the ability to precisely quantify C3b deposition is no longer just a laboratory...
Leukemia is a generic term for cancers of the bone marrow and lymphatic system. Leukemia is the most common disease in adults over 55 years old, while it is also the most often cancer in children under 15 years old. There are four main types of leukemia, each named for the rate at which the disease progresses and worsens as well as the blood cell type affected.
This approach will...
Biotechnology is witnessing a surge of innovation in phage discovery, with new functional screening platforms reshaping drug development and antibody engineering. Recent advancements highlight how phage display is evolving from a binding-focused tool into a powerful engine for therapeutic breakthroughs.
Functional Target Screening: Moving Beyond Binding
Traditional phage display often...
Sarcomas is a malignant solid tumor with high heterogeneity, which includes a large number of unique subtypes, more than 60 types. In recent years, targeted therapy based on the molecular and genetic phenotype of individual sarcomas has been a promising option for the treatment of sarcomas, meanwhile, several drugs have been approved for use to treat sarcomas.
Although some of the...
As biopharmaceutical pipelines expand and therapeutic modalities grow more complex, the demand for highly specific, reproducible, and customizable antibodies has never been greater. Two categories—post‑translational modification (PTM)–specific antibodies and anti‑idiotype (anti‑ID) antibodies—have become essential tools for both discovery research and regulated bioanalytical...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
